DIGITAL EDITION

ARCHIVES

CURRENT ISSUE

Suzetrigine: A Newly FDA-Approved Non-Opioid Treatment Option for Management of Moderate to Severe Acute Pain

Innov Clin Neurosci. 2026;23(4–6):56–61. by Alexandra R. Rola, PharmD; Jared R. Bagley, PhD; and Emily E. Leppien, PharmD, BCPS, BCPP All authors are with the Binghamton University School of Pharmacy

An Overview of Medical Errors in Psychiatry, Part 2: Preventing and Managing Medical Errors

Innov Clin Neurosci. 2026;23(4–6):62–63. by Charles D. Cash, JD, LLM Mr. Cash is Associate Director of Risk Management at Professional Risk Management Services (PRMS). FUNDING: No funding was provided for

The Association of Alzheimer’s Disease and Related Dementias Blood-Based Biomarkers With Depressive Symptoms

Research Summary: Depressive symptoms are common in older adults and have been associated with risk of Alzheimer’s disease and Alzheimer’s disease and related dementias (AD/ADRD), but the mechanisms and biomarkers

2026 AAN Annual Meeting Highlights

Rising mortality related to early-onset Alzheimer’s disease in the United States: trends and disparities, 2003–2023. This retrospective population-based study used Centers for Disease Control (CDC) and Prevention WONDER data to

Journal Watch: Alzheimer’s disease

Neuroplasticity and Alzheimer’s disease Gashtrodkhani AA, Shirkouhi SG, Khatami SS, et al. J Integr Neurosci. 2026;25(1):48051. Summary. In a narrative review of literature investigating neuroplasticity related to Alzheimer’s disease, researchers

Enhancing Alzheimer Disease Detection Using Neuropsychiatric Symptoms: The Role of Mild Behavioral Impairment in the Revised NIA-AA Research Framework

Reprinted with permission. J Geriatr Psychiatry Neurol. 2026;39(3):277–287.* by Rebeca Leon, MSc; Maryam Ghahremani, PhD; Dylan X. Guan, BSc; Eric E. Smith, MD; Henrik Zetterberg, MD; and Zahinoor Ismail, MD